Literature DB >> 9852392

Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.

K Kudoh1, Y Kikuchi, T Kita, T Tode, M Takano, J Hirata, Y Mano, K Yamamoto, I Nagata.   

Abstract

This study was designed to evaluate the clinical significance of the use of preoperative serum tumor markers in primary epithelial ovarian cancer. Subjects comprised 111 patients with primary epithelial ovarian cancer. Lactate dehydrogenase (LDH), alpha-hydroxybutyrate dehydrogenase (HBDH), carcinoembryonic antigen (CEA), CA19-9, tissue polypeptide antigen (TPA), CA125 and sialyl TN (STN) serum levels were measured within 7 days before surgery. The tumor marker values were compared with the histopathologic diagnosis. The overall agreement between the test results and the actual outcome was calculated using Student's t test and analysis of variance (ANOVA). Survival curves were constructed according to the Kaplan-Meier method, and differences in survival were assessed with the log-rank test. The prognostic significance of tumor markers for survival was assessed in a multivariate analysis with the Cox proportional hazards model. Of the tumor markers examined in this study, CA125 showed the highest positive rate (77.6%), followed by 63.2% for STN and 55.9% for CA19-9. When the positive rate was compared according to histologic types, serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid adenocarcinoma and clear cell carcinoma showed the highest positive rates for CA125 (94.1%), CA19-9 (76.9%), CA125 (91.7%) and STN (75.0%), respectively. Regarding the distribution of tumor marker levels according to the FIGO stage, LDH, HBDH, TPA and CA125 were correlated with the clinical stage while CEA, CA19-9 and STN did not show any correlation. From analyses of tumor marker levels according to histologic types, all patients with a ratio of CA125 to CEA of >1, 000 had serous cystadenocarcinoma and a ratio of CA125 to CA19-9 of >50 showed serous cystadenocarcinoma or endometrioid adenocarcinoma. On the other hand, all patients with a ratio of LDH or HBDH to CA19-9 of <1.0 had mucinous cystadenocarcinoma or clear cell carcinoma. From univariate analysis, the survival time of patients with elevated CA125, TPA or STN was significantly shorter than that of patients with normal CA125, TPA or STN levels. When the Cox's proportional hazard model was used, we identified age, clinical stage, clear cell carcinoma and serum STN as independent prognostic factors. Serum CA125, TPA or STN may give significant prognostic information in epithelial ovarian carcinoma. It is noteworthy that STN has been identified as an independent prognostic factor and has a high rate of positivity in clear cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9852392     DOI: 10.1159/000010062

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  9 in total

1.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.

Authors:  N Scholler; N Fu; Y Yang; Z Ye; G E Goodman; K E Hellström; I Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Abnormally high level of CA-19-9 in a benign ovarian cyst.

Authors:  Seung-Yeon Pyeon; Ji Young Park; Kyung-Do Ki; Jong-Min Lee
Journal:  Obstet Gynecol Sci       Date:  2015-11-16

3.  Determination of cancer antigen 125 in ovarian carcinoma.

Authors:  V Thakur; A K Anand; U Mukherjee; D Ghosh
Journal:  Indian J Clin Biochem       Date:  2003-07

4.  Bilateral Primary Ovarian Clear Cell Carcinoma in an Iranian Woman: a Case Report.

Authors:  Fatemeh Samiee-Rad; Mahdi Ghaebi; Arezoo Bajelan
Journal:  Indian J Surg Oncol       Date:  2020-10-01

5.  Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.

Authors:  Noriaki Arakawa; Hiroshi Kobayashi; Naohiro Yonemoto; Yusuke Masuishi; Yoko Ino; Hiroshi Shigetomi; Naoto Furukawa; Norihisa Ohtake; Yohei Miyagi; Fumiki Hirahara; Hisashi Hirano; Etsuko Miyagi
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

6.  Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.

Authors:  Yukihide Ota; Shiro Koizume; Yoshiyasu Nakamura; Mitsuyo Yoshihara; Tomoko Takahashi; Shinya Sato; Shohei Myoba; Norihisa Ohtake; Hisamori Kato; Tomoyuki Yokose; Etsuko Miyagi; Yohei Miyagi
Journal:  Oncol Rep       Date:  2021-01-20       Impact factor: 3.906

7.  Incidence and predictive factors for recurrent clear cell ovarian carcinoma: results from a single center in Thailand.

Authors:  Wikanda Hemman; Athithan Rattanaburi
Journal:  Obstet Gynecol Sci       Date:  2022-02-23

8.  Serum biomarkers for early detection of gynecologic cancers.

Authors:  Yutaka Ueda; Takayuki Enomoto; Toshihiro Kimura; Takashi Miyatake; Kiyoshi Yoshino; Masami Fujita; Tadashi Kimura
Journal:  Cancers (Basel)       Date:  2010-06-14       Impact factor: 6.639

9.  Sialyl-tn in cancer: (how) did we miss the target?

Authors:  Sylvain Julien; Paula A Videira; Philippe Delannoy
Journal:  Biomolecules       Date:  2012-10-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.